Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

FIVE PRIME THERAPEUTICS INC (FPRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
17.23(c) 17.56(c) 17.26(c) 17.26(c) 17.46(c) Last
194 662 274 510 131 229 190 155 173 451 Volume
+2.13% +1.92% -1.71% 0.00% +1.16% Change
More quotes
Financials (USD)
Sales 2018 68,1 M
EBIT 2018 -150 M
Net income 2018 -151 M
Finance 2018 135 M
Yield 2018 -
Sales 2019 52,2 M
EBIT 2019 -172 M
Net income 2019 -172 M
Finance 2019 174 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 6,95x
EV / Sales2019 8,32x
Capitalization 608 M
More Financials
Company
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.The FPA008 is an antibody that inhibits colony stimulating factor-1,... 
More about the company
Surperformance© ratings of Five Prime Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on FIVE PRIME THERAPEUTICS IN
07/11Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks
AC
06/11FIVE PRIME THERAPEUTICS : to Present at Goldman Sachs 39th Annual Global Healthc..
BU
06/07FIVE PRIME THERAPEUTICS : to Present at Jefferies 2018 Global Healthcare Confere..
AQ
06/07FIVE PRIME THERAPEUTICS : Walks to End Pancreatic Cancer at PurpleStride San Fra..
AQ
06/04FIVE PRIME THERAPEUTICS : Presents Bemarituzumab Trial-in-Progress Poster at the..
AQ
06/04FIVE PRIME THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (f..
AQ
06/03FIVE PRIME THERAPEUTICS : Presents Bemarituzumab Trial-in-Progress Poster at the..
BU
05/31FIVE PRIME THERAPEUTICS : to Present at Jefferies 2018 Global Healthcare Confere..
BU
05/30FIVE PRIME THERAPEUTICS : Announces Collaboration with Roche to Develop Companio..
BU
05/29FIVE PRIME THERAPEUTICS : Walks to End Pancreatic Cancer at PurpleStride San Fra..
BU
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/07Brokerages Anticipate Five Prime Therapeutics Inc $FPRX Will Post Earnings of.. 
07/05Five Prime Therapeutics Inc $FPRX Receives $34.71 Average PT from Brokerages .. 
06/30"Every luxury of the new buildings is designed to pull its residents inward—t..
10
06/28Five Prime Therapeutics $FPRX Cut to “Hold” at Zacks Investment Research  
06/28$6.25 Million in Sales Expected for Five Prime Therapeutics Inc $FPRX This Qu.. 
More tweets
Qtime:91
News from SeekingAlpha
07/06Biogen leads biotechs into positive territory 
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
06/15Five Prime Therapeutics (FPRX) Presents At Goldman Sachs 39th Annual Global H.. 
06/15Premarket analyst action - healthcare 
06/07Five Prime Therapeutics (FPRX) Presents At Jefferies 2018 Global Healthcare C.. 
Chart FIVE PRIME THERAPEUTICS IN
Duration : Period :
Five Prime Therapeutics In Technical Analysis Chart | FPRX | US33830X1046 | 4-Traders
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 38,6 $
Spread / Average Target 123%
EPS Revisions
Managers
NameTitle
Aron M. Knickerbocker President, Chief Executive Officer & Director
Lewis T. Williams Executive Chairman
Linda M. Rubinstein Chief Financial & Accounting Officer
Helen Collins Chief Medical Officer & Senior Vice President
Bryan Irving Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC-20.35%608
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250